MedTrace Logo

Hexvix Photodynamic Therapy in Patients With Bladder Cancer

NCT01303991 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2011-02-25

No results posted yet for this study

Summary

The purpose of the study is to investigate the safety and feasibility of Hexaminolevulinate based photodynamic therapy in patients with intermediate or high-risk transitional cell carcinoma of the bladder.

Conditions

  • Intermediate or High-risk Bladder Cancer

Interventions

OTHER

Hexvix PDT with Karl Storz T-Light

Sponsors & Collaborators

  • Karl Storz

    collaborator UNKNOWN

  • Photocure

    lead INDUSTRY

Principal Investigators

  • Dirk Zaak, MD · Urology Department, Medizinische Fakultät der LMU Muenchen

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2008-08-31
Completion
2008-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01303991 on ClinicalTrials.gov